ECLIA技术测定CYFRA21-1在肺癌鉴别诊断上的应用价值

来源 :中国实验诊断学 | 被引量 : 0次 | 上传用户:luomingasdf
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的 建立厦门地区正常人群电化学发光免疫分析 (ECLIA)方法的血清CYFRA2 1 1参考值范围 ;探讨运用ECLIA技术测定血清CYFRA2 1 1水平在肺癌鉴别诊断方面的应用价值。方法 选用两株高特异性抗CYFRA2 1 1单克隆抗体KS19 1和BM 19 2 1,用ECLIA夹心法 ,测定 97例肺部疾病和 70例正常人血清CYFRA2 1 1水平。结果 肺癌组血清CYFRA2 1 1水平为 32 0 0± 39 2 5 ,明显高于正常对照组 1 84± 0 6 5和肺良性疾病组 1 80± 0 84。结论 CYFRA2 1 1可作为肺癌的辅助诊断指标及与其他肺良性疾病的鉴别诊断指标 Objective To establish the reference range of serum CYFRA2 1 1 in the electrochemiluminescence immunoassay (ECLIA) method for normal population in Xiamen and to explore the application value of CYFRA2 11 in the differential diagnosis of lung cancer using ECLIA technique. Methods Two high-specific anti-CYFRA2 1 1 monoclonal antibodies KS19 1 and BM 19 2 1 were used to measure the levels of CYFRA2 11 in 97 cases of lung diseases and 70 cases of normal subjects by ECLIA sandwich method. Results The serum level of CYFRA2 1 1 in the lung cancer group was 32 0 0 ± 39 2 5, which was significantly higher than that of the normal control group 1 84 ± 0 5 5 and the lung benign disease group 1 80 ± 0 84. Conclusion CYFRA2 1 1 can be used as an auxiliary diagnosis index of lung cancer and differential diagnosis index with other benign pulmonary diseases
其他文献